TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ionis Pharmaceuticals ( (IONS) ) has issued an update.
On November 17, 2025, Ionis Pharmaceuticals completed a private offering of $770 million in 0.00% Convertible Senior Notes due 2030. The proceeds, estimated at $751.2 million after expenses, are intended for repurchasing existing 2026 Notes and general corporate purposes. This strategic financial move is expected to strengthen Ionis’s market position by refinancing existing debt and potentially impacting its stock price through market activities related to the repurchase transactions.
The most recent analyst rating on (IONS) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
Spark’s Take on IONS Stock
According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.
Ionis Pharmaceuticals’ overall stock score is driven by strong earnings call performance and positive technical indicators. However, financial performance and valuation concerns, including ongoing losses and high leverage, weigh down the score. The company’s strategic advancements and product launches provide a positive outlook, but financial risks and valuation challenges remain significant.
To see Spark’s full report on IONS stock, click here.
More about Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a pioneering company in the field of RNA-targeted medicines, with a focus on developing treatments for serious diseases. The company has a strong presence in neurology, cardiometabolic, and other areas with high patient need, and is known for its innovative approaches in RNA therapies and gene editing.
Average Trading Volume: 2,737,144
Technical Sentiment Signal: Buy
Current Market Cap: $11.59B
For detailed information about IONS stock, go to TipRanks’ Stock Analysis page.